trending Market Intelligence /marketintelligence/en/news-insights/trending/d9J6uYnQKRSHEDBXGZlqPQ2 content esgSubNav
In This List

Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Thermo Fisher Scientific Inc. and Juno Therapeutics Inc. entered into a partnership for Juno to use Thermo Fisher's Cell Therapy Systems activation reagents in the manufacturing of its chimeric antigen receptor T cell, or CAR-T cell, therapies.

Under the seven-year nonexclusive licensing and supply agreement, Thermo Fisher granted Juno rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for Juno's current and future CAR-T cell therapies, which work by manipulating a patient's own disease-fighting T-cells and then infusing them back into the body to fight blood cancers.

CTS Dynabeads activate and expand T-cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.

The companies did not disclose the financial details of the transaction.